I
nherited gene defects cause a significant fraction of both hearing loss and cardiomyopathy. Hearing loss is the most prevalent human sensory defect; in developed countries, a genetic cause accounts for Ϸ60% of early-onset hearing loss. More than 40 different nonsyndromic deafness loci have been reported. Cochlear hair cell and/or neuronal malfunction of the inner ear cause sensorineural hearing loss (SNHL). [1] [2] [3] [4] Dilated cardiomyopathy (DCM), a disorder characterized by ventricular dilation and contractile dysfunction, is a leading cause of heart failure, with a prevalence of 36.5 per 100 000 individuals. 5 Several studies indicate that 25% to 30% of DCM is familial, 6 -8 but the definition of the genomic location of the disease loci and the identification of disease genes has been hindered both by the significant mortality and the late age of onset of this disease. Nevertheless, 7 DCM loci (CMD1A-G) have been defined in this genetically heterogeneous disease. 9 -15 Although the disease genes at these loci have not been identified, 2 disease genes for DCM, actin and desmin, have been identified by candidate gene approaches. 16, 17 Many human syndromes exhibit heart and ear abnormalities in association with other organ disease. 18 Alstrom syndrome, which was recently mapped to chromosome 2p12 to 13, 19 causes DCM and hearing impairment in the setting of cone-rod ocular dystrophy, obesity, and non-insulindependent diabetes. 20 Rosenberg syndrome causes X-linked cardiomyopathy and SNHL with hyperuricemia and ataxia. 18 Mutations in mitochondria tRNAs perturb cardiac function and hearing, [21] [22] [23] but they typically have associated encephalomyelopathy, skeletal myopathies, and/or metabolic abnormalities; these defects are further distinguished by matrilineal inheritance.
The finding of cardioauditory disease in the absence of other disease is rare. The classic example is Jervell and Lange-Nielsen syndrome, a disorder characterized by congenital deafness and cardiac arrhythmias (long-QT syndrome); notably, in this disease, cardiac structure is normal. Genetic studies of Jervell and Lange-Nielsen syndrome have demonstrated that recessive mutations in the KVLQT1 gene on chromosome 11p15.5 or the ISK gene on chromosome 21q22.1 to 22.2 24, 25 cause this disorder.
We report a new heritable cardioauditory syndrome characterized by postlingual SNHL with DCM and demonstrate that the causal mutation maps to chromosome 6q23 to 24 (locus designation CMD1J). This unique phenotype provides advantages for the identification of candidate genes and establishes an early marker for identifying individuals at risk for significant cardiac disease.
Methods

Clinical Evaluations
Studies were performed in accordance with the Brigham and Women's Hospital committee for the protection of human subjects from research risks. All family members were evaluated by clinical history, physical and otoscopic examination, 12-lead ECG, transthoracic 2D echocardiography, and audiological evaluations (air and bone audiograms performed at standard audiometric frequencies and recorded monosyllable lists at phonetically balanced maximum). Echocardiographic measurements of left ventricular wall thickness and cavity dimensions were determined from M-mode tracings. DCM was diagnosed on the basis of a left ventricular end-diastolic dimension Ͼ95% for normal individuals 26 and/or fractional shortening Ͻ30% 27 in the absence of known systemic or other cardiovascular disease.
Hearing was assessed by air and bone conduction and word recognition, as determined using 50-item Central Institute for the Deaf Wordlist 22 on compact disk. 28 The level for word-recognition testing was set to a region of maximum performance as predicted by the Articulation Index, and it was never Ͻ55 dB of hearing loss. 29 Hearing deficits were classified as absent, mild, moderate, moderate/ severe, severe, or profound on the basis of the degree of hearing loss at Ͻ27, 27 to 40, 41 to 55, 56 to 70, 71 to 90, and Ͼ90 dB of hearing level, respectively. 1 Disease status of deceased individuals was based on medical records.
Genetic Studies
Linkage studies were performed using DNA extracted from whole blood or Epstein Barr virus-transformed lymphocytes, as previously described. 30 Linkage analyses used short tandem repeat markers spaced Ϸ10 cM apart (Weber 8.0 Panel, Research Genetics). Polymerase chain reaction amplification was performed in a 10-L reaction containing 20 ng of genomic DNA, fluorescence-labeled primers, and standard reagents for standard reaction times. Reaction products were pooled and mixed with size standards according to the manufacturer's recommendations (Applied Biosystems Inc). Product sizes were determined on a 6% denaturing polyacrylamide gel using an ABI 377, with Genescan and Genotyper software (Perkin-Elmer). Alleles were determined without knowledge of clinical status.
Two-point logarithm of odds scores were calculated using MLINK (version 5.1), assuming a penetrance of 95% and a phenocopy rate of 0.001. Allele frequencies were determined from genotypes of unrelated individuals.
The order of loci used in haplotype constructions was based on the physical mapping data derived from the Whitehead Physical Mapping Project 31 or determined using physical mapping of a yeast artificial chromosome contig. Candidate genes and expressed sequence tags were defined within the disease interval on the basis of yeast artificial chromosome content mapping.
Mutational Analysis of Epicardin
A 10-kilobase EcoRI fragment of PAC 524A10 (Roswell Park Cancer Institute) containing the epicardin gene was identified by hybridization with an epicardin cDNA probe (amplified using primers exon 1a-F and exon 2-R, below). This PAC maps to the human 6q23 to 24 region. 32 A 10 kb fragment was subcloned into pBluescript. Positive clones selected by hybridization to this cDNA probe were expanded for DNA extraction (Qiagen) and sequenced using ABI 377 Big Dye sequence technology. Exon-intron boundaries were deduced from comparison with the cDNA sequence (Genbank accession number AF047419 33 ). Primers corresponding to intron sequences external to splice signals were constructed and used to amplify and sequence exons encoding epicardin, as follows:
Exon 1a-F: CATTCGGGAGGCCTCTTGGTTTCA Exon 1a-R: CCGCTCAGGGGGCTCTTCTTG Exon 1b-F: CGGCGGCCTGGGCAAGAG Exon 1b-R: GCGCCCTCACCCCCACTCC Exon 2-F: CCTTTCATCTCAGGCCCCGAGTCC Exon 2-R: GTTCTCGCGGGGTGGGACAG Sequences of samples from affected and unaffected individuals were compared using ABI 377 and DNA-Star SeqMan software.
Results
The unusual disease phenotype in family MCE was recognized when 2 brothers (Individuals III-3 and III-5, Figure 1 ) with unexplained SNHL of Ͼ20 years duration developed progressive heart failure that necessitated cardiac transplantation. Coronary angiography in both excluded significant coronary artery disease. Family history and medical records revealed 4 deceased individuals with both hearing loss and heart disease; 3 died of heart failure (I-1, II-2, and II-3) and 1 died suddenly (III-2). Clinical evaluations of surviving family members demonstrated left ventricular dilation and/or dysfunction in 6 adult individuals ( Figure 1 and Table 1) ; each also had hearing loss. Audiogram profiles obtained in affected individuals showed symmetric deficits in left and right air and bone conduction (Figure 2 ). SNHL was also detected in 3 individuals (IV-1, IV-3, and IV-5) who had no echocardiographic evidence of ventricular dilation or dysfunction, although individual IV-1 had a history of clinical heart failure after intravenous hydration. The status of individual IV-6 was uncertain: this individual was 27 years old, had mild hearing deficits, and a history of frequent ear infections during childhood.
Three of four individuals with DCM in family MDB ( Figure 3 ) also had SNHL. Family history and medical records indicated hearing deficits occurred by early adulthood and preceded cardiac symptoms. Audiological evaluations were not performed on individual I-2, and her hearing phenotype was assigned unknown status. Progressive congestive cardiomyopathy characterized the DCM found in family MDB and caused the death of 2 individuals (II-1 and II-4); in one instance, death was sudden. Individual II-6 has been listed for cardiac transplantation. Significant coronary disease was excluded in some individuals by angiography (II-4, II-6) or autopsy (II-1).
The gross pathological examination of the heart specimen obtained from individual III-2 from family MCE revealed an enlarged, globular heart weighing 620 g. Histological examination demonstrated hypertrophic myocytes with enlarged hyperchromatic nuclei and increased interstitial fibrous connective tissue. Comparable findings of idiopathic DCM were described in the pathology reports of explanted hearts from individuals III-3 and III-5.
Pedigree analyses of families MCE and MDB were consistent with autosomal-dominant inheritance and age-related penetrance of SNHL (onset in second decade) with DCM (onset in fourth decade). Karyotypes of affected individuals from each family were normal (data not shown). Genomewide linkage analyses were performed to map the disease locus in family MCE. The analysis of 280 polymorphic loci excluded Ͼ80% of the genome before linkage was identified with markers at 6q23 to 24 (Table 2) . When the 4 young individuals (IV-1, IV-3, IV-5 and IV-6; Ͻ40 years) with SNHL but no clinical signs of cardiomyopathy were assigned an "unknown" status for linkage analyses, a maximum logarithm of odds score of 3.98 (at ϭ0) was achieved at locus D6S2411. However, if either SNHL or DCM was used as the diagnostic criterion for disease, the maximum logarithm of odds was 4.88 (at ϭ0), indicating a likelihood of 75 000:1 that the disease gene is encoded in this region.
To refine the disease interval, genotypes were analyzed at nearby loci (Figure 4) , and a disease haplotype was deduced (Figure 1 ). Recombination events were identified in 2 individuals: genotype was discordant with affection status in II-3 at D6S975 and in III-2 at D6S292, thereby defining a disease interval that spans 2.8 cM.
Analyses of chromosome 6q23 to 24 polymorphic loci in family MDB neither proved nor excluded linkage due to the limited size of this pedigree. The disease alleles found in affected individuals of family MCE were not present in individual II-6 of family MDB, which excluded a shared disease haplotype.
Candidate Gene Analysis
The disease interval contains 7 known genes-epicardin, c-Myb, SGK, EYA4, TLP, Btf, and eRFS-and several other genes encoding expressed sequence tags. The mesenchymal basic helix-loop-helix transcription factor epicardin (also known as capsulin and Pod-1), 34, 35 has been mapped to a region of mouse chromosome 10 that is syntenic to human chromosome 6q23 to 24. 36 Epicardin expression has been demonstrated during murine cardiac development and in interstitial cells of the adult mouse myocardium. 37 We detected epicardin transcripts in human cardiac and cochlear cDNA libraries (data not shown) and amplified epicardin sequences from the overlapping yeast artificial chromosome clones 917C6 and 916H10 and P1 artificial chromosomes clone 524A10, which are contained in the disease interval. To determine if a deletion or rearrangement of the epicardin gene caused SNHL and DCM in family MCE, Southern blot analyses (after EcoR1, HindIII, and BamHI restriction enzyme digests) were performed; they were identical in DNA derived from 3 affected and 3 unaffected individuals (data not shown). DNA sequence analyses of epicardin exons and flanking splice signals, introns, and untranslated regions were performed (data not shown). A 4-bp deletion was found in a CT-rich element in the 5Ј untranslated region, but the deletion represented a common polymorphism that did not segregate with disease. Because some affected individuals were heterozygous for this polymorphism, the disease-causing mutation cannot be a large deletion of the entire epicardin gene. We did not detect any epicardin gene defects that could cause SNHL and DCM in affected members of family MCE.
Discussion
We report a new heritable syndrome, characterized by autosomal-dominant SNHL with DCM in 2 unrelated families and demonstrate that the causal gene(s) reside on chromosome 6q23 to 24. Cardiac disease occurred with hearing deficits; both phenotypes exhibited age-related penetrance. Early in childhood, hearing was normal, but deficits evolved throughout the school-age years and typically became overt by the second decade of life. Cardiac disease was similarly insidious in onset, but it subsequently demonstrated a rapidly progressive clinical course. Echocardiographic examinations demonstrated left-ventricular dilation with reduced systolic function by the third decade of life, but cardiac symptoms were unusual before 40 years of age. Throughout the fifth and sixth decades, heart failure was common; it necessitated transplantation or caused death in all affected individuals. Two disease genes, DFNA10 38 and CMD1F, 9 map in or near the CMD1J locus. DFNA10 is responsible for deafness in affected members of several large families. Although heritable heart disease was not recognized as a feature of deafness caused by DFNA10, we cannot exclude the possibility that a different defect in the same gene or a defect in a contiguous gene could account for the cardiac defects in MCE family members. Although CMD1F mutations do cause DCM, we do not think that these loci are allelic for several reasons. (1) The disease intervals do not overlap. (2) Hearing loss has not been observed in individuals with CMD1F mutations. (3) The skeletal myopathy seen with the CMD1F mutation was not observed in our patients.
SNHL with DCM in families MCE and MDB could reflect a mutation of a single protein with important biological function in both the ear and heart, as in Jervell and LangeNielsen syndrome (long-QT syndrome with deafness). Mutations in K ϩ channel components encoded by KVLQT1 or ISK genes cause this recessive disorder. In the heart, these defects delay myocellular repolarization, 39 whereas in the ear, mutations prevent the secretion of potassium into endolymph, changing the ionic environment necessary for normal hair cell function. 40 Although we hypothesized that mutations in epicardin, a basic helix-loop-helix transcription factor encoded within the disease interval and expressed in cardioauditory tissues, might cause SNHL with DCM, no defects were identified. Continued analyses of genes that are coexpressed in these tissues may help explain the pleiotropic phenotypes found in families MCE and MDB. These data extend the heterogeneity of human mutations that cause DCM. Although the incidence of hereditary cardioauditory disease is likely low, the clinical recognition and dissection of the molecular cause of this disorder has value for identifying molecules whose function is critical for cardiac biology. The late onset of disease and premature death are substantial hurdles that limit the power of molecular genetic approaches to study DCM. Indeed, genome-wide linkage analyses of the cardiac phenotype in family MCE might have been difficult. However, the recognition of hearing deficits that preceded heart disease, thus allowing SNHL to indicate affection status, significantly increased the power of genetic studies. Coexistence of disease in the myocardium and inner ear will also be of use in ongoing efforts to identify the disease gene. More immediately, recognition of the association between hearing deficits and cardiomyopathy has clinical importance. The identification of SNHL in an individual can prompt close monitoring and early intervention, practices that may ultimately reduce the high morbidity and mortality of DCM in these families.
